Your Health
Our Science
Our Company
Investors
Careers

Your Health
Our Science
Our Company
Investors
Careers

Update
FDA approves our new treatment for classic congenital adrenal hyperplasia (CAH)
Learn more >

Investor Overview
Stock Information
Financial Communications
News Releases
Corporate Governance
Sustainability
Business Development
Webcasts & Presentations

Annual Meeting

View Documents for the 2024 Annual Meeting of Shareholders

This site uses cookies to ensure you get the best experience on our website.

Learn More

You are leaving Neurocrine.com

Continue

Diseases & Conditions
News & Media
Approved Medicines
Careers
Investigational Therapies
Leadership
Pipeline
Investors
Clinical Studies
Our Responsibility

Follow Us

© 2024 Neurocrine Biosciences, Inc. All Rights Reserved.

Contact
Privacy Policy
Cookie Policy
Terms & Conditions
Accessibility
Sitemap